Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CFXA - Colfax Corp
4.23(2.28%)5:28:19 PM 2/24/2021
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 


Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.


  • MACD is crossing MACD signal line at 2.0. MACD crossing signal line is bullish signal.
Stock Statistics
PE Ratio
PEG Ratio
P/S (ttm)1.3
Earning Growth (QoQ)28%
Revenue Growth (QoQ)
Short %0%
Held by Institutions %99%
1 Day Vol Adjusted Return-0.3
1 Month Vol Adjusted Return3.0
3 Month Vol Adjusted Return13.7
6 Month Vol Adjusted Return10.8
20 Days SMA Price ZScore2.1
50 Days SMA Price ZScore2.8
12 -26 Days PPO2.7
1 Month Average Short Volume Ratio47.6
1 Day Volume Change ZScore-0.2
1 Month Daily Vol3.1
Related Topics
leak data

Related Topics

Stock news

    Philip Okala Appointed to Colfax Board of Directors

    Annapolis Junction, MD, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it has appointed Philip Okala, Chief Operating Officer of the University of Pennsylvania Health System, to its Board of Directors. This appointment increases the size of Colfax’s Board of Directors to eleven members. Mitchell P. Rales, Chairman of the Board of Colfax, said, “We are very pleased to have Phil join our Board. He has extensive exper...

    Is Now The Time To Put Colfax (NYSE:CFX) On Your Watchlist?

    Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...

    Colfax Corp (CFX) Q4 2020 Earnings Call Transcript

    CFX earnings call for the period ending December 31, 2020.

    Colfax: Q4 Earnings Insights

    Shares of Colfax (NYSE:CFX) rose 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 16.39% year over year to $0.51, which beat the estimate of $0.50. Revenue of $828,122,000 decreased by 6.78% year over year, which missed the estimate of $830,720,000. Guidance Q1 EPS expected to be between $0.35 and $0.40. How To Listen To The Conference Call Date: Feb 18, 2021 View more earnings on CFX Time: 08:00 AM ET Webcast URL:

    Colfax Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 18, 2021 / Colfax Corp. (NYSE:CFXA) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 18, 2021 at 8:00 AM Eastern Time.

    Colfax Announces Fourth Quarter 2020 Results and 2021 Growth Outlook

    • Reported $0.29 EPS from continuing operations and achieved $0.51 of adjusted EPS• Recently acquired two high-growth, high-gross margin medical technology businesses • Announced 2021 outlook with expectations for significant revenue, profit and cash flow growth • Scheduled Investor Day for Thursday, March 11, 2021 ANNAPOLIS JUNCTION, MD, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the fourt...

    Colfax Schedules Fourth Quarter 2020 Earnings Release and Conference Call

    Annapolis Junction, MD, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the fourth quarter of 2020 on the morning of Thursday, February 18, 2021. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (Intern...

    Colfax's (CFX) Unit Closes Buyout of Trilliant Surgical

    Colfax (CFX) arm DJO closes buyout of Trilliant Surgical, which will boost its product offerings and growth prospects in the foot and ankle surgery market.

    DJO® Acquires Trilliant Surgical

    DJO, LLC (DJO or the Company), a leading global provider of medical technologies to get and keep people moving, today announced the acquisition of Trilliant Surgical®, a national provider of foot and ankle orthopedic implants. The acquisition of Trilliant Surgical’s leading product technologies and clinical efficacy supports DJO’s focused expansion into the adjacent high-growth $1 billion US foot and ankle market.